225 related articles for article (PubMed ID: 12630975)
1. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
[TBL] [Abstract][Full Text] [Related]
2. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
[TBL] [Abstract][Full Text] [Related]
3. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis of the major metabolites of capecitabine.
Gieschke R; Reigner B; Blesch KS; Steimer JL
J Pharmacokinet Pharmacodyn; 2002 Feb; 29(1):25-47. PubMed ID: 12194534
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
Reigner B; Watanabe T; Schüller J; Lucraft H; Sasaki Y; Bridgewater J; Saeki T; McAleer J; Kuranami M; Poole C; Kimura M; Monkhouse J; Yorulmaz C; Weidekamm E; Grange S
Cancer Chemother Pharmacol; 2003 Sep; 52(3):193-201. PubMed ID: 12783206
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Urien S; Rezaí K; Lokiec F
J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):817-33. PubMed ID: 16284918
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
Cassidy J; Twelves C; Cameron D; Steward W; O'Byrne K; Jodrell D; Banken L; Goggin T; Jones D; Roos B; Bush E; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 1999; 44(6):453-60. PubMed ID: 10550565
[TBL] [Abstract][Full Text] [Related]
8. Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.
Fischel JL; Formento P; Ciccolini J; Etienne-Grimaldi MC; Milano G
Anticancer Drugs; 2004 Nov; 15(10):969-74. PubMed ID: 15514566
[TBL] [Abstract][Full Text] [Related]
9. Development of a UPLC-MS/MS Assay for the Quantitative Determination of Capecitabine, 5'-deoxy-5-fluorocytidine (5'-dFCR), 5'-deoxy-5-fluorouridine (5'-dFUR), 5'-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL).
Knikman JE; de Vries N; Rosing H; Cats A; Guchelaar HJ; Beijnen JH
Pharmazie; 2023 Aug; 78(8):107-112. PubMed ID: 37592424
[TBL] [Abstract][Full Text] [Related]
10. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Cassidy J; Twelves C; Van Cutsem E; Hoff P; Bajetta E; Boyer M; Bugat R; Burger U; Garin A; Graeven U; McKendric J; Maroun J; Marshall J; Osterwalder B; Pérez-Manga G; Rosso R; Rougier P; Schilsky RL;
Ann Oncol; 2002 Apr; 13(4):566-75. PubMed ID: 12056707
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Kuwata K; Nagayama S; Hirakawa Y; Matsushima E; Kawaguchi Y
Gan To Kagaku Ryoho; 2000 Jun; 27(6):885-90. PubMed ID: 10897216
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.
Di Desidero T; Orlandi P; Fioravanti A; Cremolini C; Loupakis F; Marmorino F; Antoniotti C; Masi G; Lonardi S; Bergamo F; Zagonel V; Falcone A; Bocci G
Invest New Drugs; 2018 Aug; 36(4):709-714. PubMed ID: 29488048
[TBL] [Abstract][Full Text] [Related]
14. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
[TBL] [Abstract][Full Text] [Related]
15. Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030).
Louie SG; Ely B; Lenz HJ; Albain KS; Gotay C; Coleman D; Raghavan D; Shields AF; Gold PJ; Blanke CD
Br J Cancer; 2013 Oct; 109(7):1744-9. PubMed ID: 24022189
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer.
Daher Abdi Z; Lavau-Denes S; Prémaud A; Urien S; Sauvage FL; Martin J; Leobon S; Marquet P; Tubiana-Mathieu N; Rousseau A
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1285-93. PubMed ID: 24801171
[TBL] [Abstract][Full Text] [Related]
17. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients.
Reigner B; Clive S; Cassidy J; Jodrell D; Schulz R; Goggin T; Banken L; Roos B; Utoh M; Mulligan T; Weidekamm E
Cancer Chemother Pharmacol; 1999; 43(4):309-15. PubMed ID: 10071982
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
Ebi H; Sigeoka Y; Saeki T; Kawada K; Igarashi T; Usubuchi N; Ueda R; Sasaki Y; Minami H
Cancer Chemother Pharmacol; 2005 Aug; 56(2):205-11. PubMed ID: 15844007
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients.
Lunar N; Etienne-Grimaldi MC; Macaire P; Thomas F; Dalenc F; Ferrero JM; Pivot X; Milano G; Royer B; Schmitt A
Cancer Chemother Pharmacol; 2021 Feb; 87(2):229-239. PubMed ID: 33386926
[TBL] [Abstract][Full Text] [Related]
20. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]